Oncology

Genetic sequencing
#Cancer research #Genetics / genomics #Next generation sequencing #Oncology #Personalised medicine #RNA sequencing #The Tecan Group #Webinar

Next-generation sequencing and oncology drug discovery

Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend on April 24 at 7AM PST / 10AM EST / 3PM BST / 4PM CET.   Join this free webinar to learn about the… Read More

Webinar date:
Brought to you by Tecan
#News

Genetic sequencing
#Cancer research #Genetics / genomics #Next generation sequencing #Oncology #Personalised medicine #RNA sequencing #The Tecan Group

How next-generation sequencing is informing oncology drug discovery

Watch this free webinar to learn about the biggest challenges and opportunities facing the NGS oncology space.   You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr… Read More

Webinar date:
Brought to you by Tecan
#Webinars

#Biopharmaceuticals #Collaboration #Contract Research Organisations (CROs) #Cryo-EM #Drug research #Immunology #Oncology

What’s next for this integrated drug discovery collaboration? 

Galapagos and NovAliX have entered a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organisation. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and… Read More

#News

#Antibodies #Cancer research #Cancer vaccine #DDW Highlights podcast #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As March draws to a close, this week’s key announcements have demonstrated the breadth of… Read More

#News

Non-small cell lung cancer
#Cancer research #Janssen #Lung cancer #Oncology #Trial data

Drug shows long-term response in aggressive lung cancer

New data has revealed a long-term response in patients with advanced non-small cell lung cancer (NSCLC) taking Rybrevant (amivantamab). The CHRYSALIS study is evaluating amivantamab in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease… Read More

#Cancer Research #News

Colon cancer
#Cancer research #Cardiff Oncology #Clinical trial #Colorectal cancer #Oncology #Phase II trial

Metastatic colorectal cancer trial launches in the US

A Phase II trial to investigate onvansertib for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) has treated its first patients. The ONSEMBLE trial is designed to demonstrate a clinically meaningful difference in response and onvansertib’s contribution to standard of care (SoC)… Read More

#Cancer Research #News

#Aptamer Group #Aptamers #Automation #Drug delivery #Gene delivery #Gene therapy #Molecular Biology #Oncology #Precision medicine #Turning Science into Business

Turning science into business: An optimised alternative to antibodies

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did… Read More

#Exclusive Content

#Antibodies #Cancer research #Cancer vaccine #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

This week in drug discovery (27-31 March)

News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer.   As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.  The… Read More

#News

Wear a hat day
#Brain #Cancer research #Charity #Drug discovery #Fundraising #Oncology

Wear a hat for brain tumour research

Today is #WearAHatDay created by Brain Tumour Research to raise awareness and funds for research into finding treatments for brain cancer. Brain Tumour Research encourages people to “look super for science and help research breakthroughs happen”. Over the last ten years, Wear A Hat Day events have raised more than… Read More

#News

#Chemotherapy #EpicentRx #FDA #Head and neck cancer #Oncology #Phase II trial

US FDA fast-tracks drug to prevent severe chemotherapy side effect

The US Food and Drug Administration (FDA) has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head and neck cancer patients. The FDA also accepted the company’s Investigational New Drug (IND) application to initiate a follow-on Phase… Read More

#News #Regulatory

Diversity
#Clinical trial design #Clinical trials #Diversity #Inato #Inclusivity #Investment #Oncology

$20 million in new funding to make clinical trials more inclusive

Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital. With the new funding, Inato will advance its diversity product offering to meet the new FDA… Read More

#Business & Investment #News #Start-up Zone

Vaccine vial and syringe
#Cancer research #Cancer vaccine #China #Oncology #Solid tumours #Vaccines

Chinese regulator approves personalised cancer vaccine trial

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. This breakthrough marks the first of its kind in China and represents a significant milestone… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #Oncology #Pancreatic cancer #Propanc Biopharma #Solid tumours #Spain #Tumour microenvironment (TME)

Proenzyme suppresses TGF-β pathway in pancreatic cancer

A Spanish study has shown that PRP, a mixture of two proenzymes, trypsinogen and chymotrypsinogen, suppresses the TGF-β pathway and the tumour microenvironment in pancreatic cancer. The study was co-led by Belén Toledo Cutillas, at the laboratory of Professor Macarena Perán, University of Jaén, Granada, Spain. Read More

#Cancer Research #Editor's Choice #News

Modern medical science laboratory
#Astellas Pharma #Cancer research #Collaboration #Computer modelling #Immuno-oncology #MIMETAS #Oncology #Partnership

Improving immuno-oncology therapies using tumour modelling

Astellas Pharma and MIMETAS, which specialises in human disease modelling, have entered a strategic partnership to develop treatments for cancer. The companies will use MIMETAS’ tumour models to support the next generation of immuno-oncological therapies. “We are excited to make this next step in… Read More

#Cancer Research #News

PD-L1 antibody
#Antibody #Cancer research #Collaboration #Merck #Oncology #Pfizer

Merck buys full rights to cancer drug Bavencio from Pfizer

Merck has bought the exclusive worldwide rights to develop, manufacture and commercialise anti PD-L1 antibody Bavencio (avelumab) from Pfizer. Merck will take full control of the global commercialisation of Bavencio through its affiliate Ares Trading. The transaction has also ended a long-term collaboration between Merck and… Read More

#Business & Investment #News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen a number of developments in the treatment of solid tumours… Read More

#News